About Dan Jing Wu

About VivArt-X

VivArt-X will revolutionize breast reconstructive surgery in women who have undergone breast tissue removal after breast cancer diagnosis. 1 in 7 women will develop breast cancer during her life. Current reconstruction methods make use the technique fat grafting, using patient’s own fat as donor and minimizes the need for complex surgical approaches. However, 50-60% of the transplanted fat cells will die, owing to bad cell engraftment. Therefore, there is an unmet need for a new breast reconstructive method to restore, reconstruct and regenerate breast tissue predictably with long term potential. VivArt-X offers a revolutionary synthetic, degradable biomaterial to achieve excellent cell engraftment, which results in personalized breast reconstruction and ultimately regeneration. VivArt-X has been nominated as one of the top 3 most promising startups of Brabant 2023 and received the Gerard & Anton Award and the European Innovation Award in 2023.